Ask The Board

  1. How Can A Cell Therapy Manufacturer Avoid The Impact Of Supply Chain Disruptions Via Single Use Systems (SUS), While Also Being Sustainable For The Environment? 7/1/2020

    See the answer from Raúl Diaz, who directs MSD Animal Health Large Molecules Biopharm Operations in Montes Claros, Brazil.

  2. What Are Strategies Biopharmas Can Use To Educate And Influence Change Within Their Organization? 7/1/2020

    See the answer from Chhaya Shah, SVP of tech ops at Radius Health.

  3. Will The “Work-From-Home” Concept Ever Take Off In The Biopharma Industry? If Yes, What Conditions/Trends Will Enable It To Happen? If Not, What Are The Barriers Stopping The Industry From Embracing This Trend? 7/1/2020

    See the answer from Leslie Williams, the former president, CEO, and founder of ImmusanT.

  4. The Emerging CAR-T Therapies Are Brilliant But Appear Challenging When Trying To Reach A Large Population Of Patients. What Is The Prognosis Of Alternatives Such As Allogenic CAR-T Becoming Mainstream? 6/1/2020

    See the answer from Sandy Macrae, CEO of Sangamo Therapeutics.

  5. In The Context Of Rising Clinical Trial Expenses, As A Result Of Increased Patient Numbers And Extended Time Frames, What Clinical Development Design Innovations Will We Observe In The Next Two To Five Years? 6/1/2020

    See the answer from Tomasz Sablinski, M.D., Ph.D., the cofounder and board member of Transparency Life Sciences.

  6. How Can The Industry Effectively Partner With Health Agencies To Revamp Clinical Trials, Which Are A Major Factor For Slow/Costly Drug R&D? 6/1/2020

    See the answer from Jeff Berkowitz, who serves on several biopharmaceutical company boards, including H. Lundbeck A/S.

  7. What Has Been The Most Fulfilling Experience You’ve Had Regarding Mentoring? 5/1/2020

    See the answer from Anu Hans, VP of strategic initiatives, Janssen supply chain.

  8. With The Growing Number Of Clinical Disappointments In Alzheimer’s Disease, How Will We Meet The Cognitive And Neurodegenerative Needs Of An Aging World Population? 5/1/2020

    See the answer from John LaMattina, Ph.D., a senior partner at PureTech Health and the former senior VP at Pfizer and president of Pfizer Global Research and Development.

  9. What Current Industry/Patient-Centricity Trends Are Encouraging Patient Participation In Clinical Trials? 5/1/2020

    See the answer from Margaret Anderson, a managing director at Deloitte. She was previously executive director at FasterCures.

  10. What Recommendations Do You Have For A Biopharma Exec Considering Consulting As A Second/ Next Career? 4/1/2020

    See the answer from Liz Bywater, Ph.D., speaker and author of Slow Down to Speed Up! She advises executives at some of the world’s most successful companies to drive growth, propel innovation, and lead change.